Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH

Inhibikase Therapeutics, Inc.

2026-Q1 EPS reported -$0.10 vs consensus -$0.11 ▲ beat (+8.6%)

Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.
R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.
Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inhibikase Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $16.4 million, or $0.10 per share, EPS $0.10 per share.

Period: the quarter ended March 31, 2026
Net income: $16.4 million, or $0.10 per share
EPS: $0.10 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.